Overview

A Study to Evaluate Thefficacy and Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized MG Patients

Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
Primary study objective: To verify the efficacy of HBM9161 subcutaneous injection in Chinese patients with gMG
Phase:
Phase 3
Details
Lead Sponsor:
Harbour BioMed (Guangzhou) Co. Ltd.